Function level | Therapy | 2007 | 2011 |
---|---|---|---|
High | DA monotherapy, n (%) | 6 (33%) | 14 (59%)b |
Daily LD equivalents, mg (mean ± SD) | 350 ± 57 | 335 ± 57 | |
LD monotherapy, n (%) | 3 (17%) | 2 (8%) | |
Daily dose, mg (mean ± SD) | 315 ± 33 | 325 ± 15 | |
DA + LD combined therapy, n (%) | 9 (50%) | 8 (33%) | |
Total daily LD equivalents, mg (mean ± SD) | 400 ± 52 | 415 ± 35 | |
Moderate | DA monotherapy, n (%) | 5 (25%) | 10 (53%)b |
Daily LD equivalents, mg (mean ± SD) | 250 ± 25 | 325 ± 33b | |
LD monotherapy, n (%) | 7 (35%) | 2 (10%)b | |
Daily dose, mg (mean ± SD) | 280 ± 25 | 275 ± 12 | |
DA + LD combined therapy, n (%) | 8 (40%) | 7 (37%) | |
Total daily LD equivalents, mg (mean ± SD) | 324 ± 34 | 330 ± 35 | |
Low | DA monotherapy, n (%) | 3 (17%) | 4 (14%) |
Daily LD equivalents, mg (mean ± SD) | 255 ± 15 | 261 ± 27 | |
LD monotherapy, n (%) | 9 (50%) | 12 (41%) | |
Daily dose, mg (mean ± SD) | 250 ± 25 | 230 ± 32 | |
DA + LD combined therapy, n (%) | 6 (33%) | 13 (45%) | |
Daily LD equivalents, mg (mean ± SD) | 289 ± 21 | 277 ± 27 |